جست‌وجوی استاد و پژوهشگر

• Radiation Oncology
• Pancreatic Cancer
• Translational Research
• +۵ مورد دیگر

Dr. Sophie Dobiasch is a clinician scientist and Junior Group Leader at the Institute of Radiation Medicine (IRM), Helmholtz Munich, and the Department of Radiation Oncology, Klinikum rechts der Isar, Technical University Munich (TUM). Since 2015, she has focused on translational research in personalized radiooncology for pancreatic cancer, integrating clinical practice and experimental studies. Education: Medical doctor (MD) at Ruprecht-Karls University Heidelberg (2008-2015). Her research explores mechanisms of radioresistance in pancreatic cancer, leveraging targeted therapies, cytotoxic agents, and herbal substances. She employs advanced techniques such as small animal imaging and high-precision irradiation to bridge lab discoveries with clinical applications. Recent publications highlight her work on phosphoproteomic analysis, radiosensitization using Curcumin, and DNA repair pathways in pancreatic cancer. These studies align with broader themes in radiation oncology, molecular biology, and translational medicine. Scientific Awards: Award for 2nd best young investigator talk (2018). Dobiasch collaborates with networks including the German Consortium for Translational Cancer Research (DKTK), SFB 1321, and the European Pancreatic Cancer Center. Her intercultural experience spans stays in Japan, Great Britain, India, and Nepal.

Maoli Duanمشاهده پروفایل

دانشیار

• Otolaryngology
• Gene Therapy
• Stem Cell Therapy
• +۳ مورد دیگر

Maoli Duan is an Associate Professor and Senior Consultant at the Karolinska Institutet , affiliated with the Department of Clinical Science, Intervention and Technology under the Ear, Nose and Throat Diseases division. With over 150 peer-reviewed publications, his translational research bridges animal models and clinical applications in otolaryngology. Academic Rank: Associate Professor (Karolinska Institutet, 2006) Doctoral Degree: Department of Physiology and Pharmacology, Karolinska Institutet (1999) Research Focus Dr. Duan's work centers on gene therapy and stem cell treatments for sensorineural hearing loss , with recent breakthroughs in AAV vector delivery for congenital deafness. His 2025 Nature Medicine study demonstrated hearing restoration in patients with OTOF gene mutations through viral gene replacement. Publication Trends His 15 most recent articles (2023-2025) span biomedical engineering , clinical otology , and translational neuroscience . Key subfields include inner ear drug delivery , cochlear implants , gene therapy protocols , and viral vector optimization . Notably, his team has pioneered non-invasive approaches to treating Meniere's disease and noise-induced hearing loss . Collaborative Networks Dr. Duan collaborates with institutions across Europe , Asia , and North America , with recurring co-authors from Karolinska Institutet , University of Gothenburg , and Shanghai Jiao Tong University . His work appears in Nature Medicine , PNAS , and Advanced Science . Scientific Context Dr. Duan's research aligns with global efforts to address genetic hearing disorders through molecular interventions. His team's clinical trials demonstrate that gene therapy can restore near-normal hearing in OTOF mutation carriers without major adverse events, opening new pathways for non-invasive auditory restoration in both pediatric and adult populations.

• Neuroscience
• Neurobiology
• Autism Spectrum Disorders
• +۳ مورد دیگر

Emanuela Santini is a Principal Researcher at the Department of Neuroscience, Karolinska Institutet since 2022, with a PhD in Neuroscience from Karolinska Institutet (2009). Her research focuses on autism spectrum disorders, Parkinson's disease, and signaling pathways like mTOR and eIF4E, often using mouse models to study synaptic plasticity, dopamine neurotransmission, and translational control. Employment: Principal Researcher, Karolinska Institutet (2022–present) Education: PhD in Neuroscience, Karolinska Institutet (2009) Her work examines the molecular basis of neurological conditions, particularly how dysregulated protein synthesis and signaling cascades contribute to autism and Parkinson's disease. She investigates mechanisms underlying Levodopa-induced dyskinesia, fear memory extinction, and synaptic dysfunction in genetic models. The 15 most recent publications highlight her interest in autism spectrum disorders, striatal signaling, and translational control pathways. Key trends include mTOR hyperactivity in ASD models, dopamine-neuron maturation during critical periods, and autophagy's role in movement disorders. Grants from the Swedish Research Council (2023) and StratNeuro bridging grants (2022) support her research. Collaborations with institutions like University of Coimbra and researchers such as Eric Klann and Gilberto Fisone demonstrate her academic network. She participates in neuroscience outreach and was acknowledged in a doctoral thesis defense (2025) as part of the academic community.

Zhiguo Liمشاهده پروفایل

استادیار

• Cancer Biology
• Toxicology
• Prostate Cancer
• +۴ مورد دیگر

Zhiguo Li is an Assistant Professor at the University of Kentucky in the Department of Toxicology and Cancer Biology. He is affiliated with multiple research programs, including the Center for Appalachian Research in Environmental Sciences (UK-CARES), Markey Cancer Center, and Molecular and Cellular Oncology Research Program. Education: Ph.D., Chinese Academy of Sciences (2011) B.S., Hebei University (2006) Zhiguo Li's research focuses on Polo-like kinase 1 (PLK1) and its role in prostate and lung cancer progression, DNA damage response, immunotherapy, and targeted therapy. His work explores how PLK1 interacts with pathways like MNK/GRP78, p300/CBP bromodomain, and BRD4 to influence tumor growth and drug resistance. He also investigates epigenetic mechanisms and metabolic reprogramming in cancer cells, aiming to develop novel therapeutic strategies. The articles extracted reveal a strong emphasis on PLK1 as a therapeutic target across cancers, particularly prostate cancer. Recent studies examine its role in androgen receptor signaling, DNA repair, and immune checkpoint regulation. Older works extend to leukemia, stress response, and plant physiology, showcasing interdisciplinary breadth. Grants: Funded by the Department of Defense (2025), National Cancer Institute (2022-2027), American Cancer Society (2020-2022), and National Institute of Environmental Health Sciences (2020). Projects include targeting proteostasis, enhancing immunotherapy, and treating arsenic-induced lung cancer. Labs and Collaborations: Works within the Molecular and Cellular Oncology Research Program and collaborates with institutions like the National Cancer Institute and American Cancer Society. Research spans tumor biology, proteostasis, and environmental carcinogenesis.

Binhua Zhouمشاهده پروفایل

استاد

• Cancer Metastasis
• Epithelial-Mesenchymal Transition
• Breast Cancer
• +۵ مورد دیگر

Binhua Zhou, Ph.D., holds the Madeline F. James and Edith D. Gardner Chair in Cancer Research at the Markey Cancer Center, University of Kentucky. He serves as Professor in the Department of Molecular and Cellular Biochemistry, Director of the Breast Cancer Research Program, and Program Leader for the Molecular and Cellular Oncology Research Program. His academic qualifications include a Doctor of Medicine from Guangzhou Medical College (1986), a Ph.D. from the University of Texas at Austin (1996), and postdoctoral training at the University of Texas Health Science Center (2001). Dr. Zhou's research focuses on molecular mechanisms of cancer metastasis, particularly epithelial-mesenchymal transition (EMT) regulation by Snail/Slug transcription factors in breast and pancreatic cancers. Key areas include metabolic reprogramming in metastasis, signaling pathway alterations, and therapeutic targeting of NNMT in triple-negative breast cancer. His work employs biochemical, molecular, and cellular approaches to identify targets for metastasis prevention. Analysis of recent publications (2020-2025) reveals dominant themes: EMT-linked metabolic adaptation, ferroptosis suppression, STAT3/SNAIL synergy in metastasis, and myeloid cell regulation in breast cancer. His group consistently explores intersections between transcriptional control, tumor metabolism, and microenvironment remodeling. Awards & Honors Young Investigator Award for Breast Cancer Research (1998) Alexander Wang Memorial Award, 3rd Prize (2000) Career Development Award, Ovarian Cancer Spore Program (1999) Wethington Excellence in Research Award (2009) Award for Cancer Research (2009) Dr. Zhou leads multiple NIH-funded projects as Principal Investigator, including NCI grants targeting NNMT in breast cancer progression and DoD-funded obesity-cancer initiatives. He directs the Breast Cancer Research Program, coordinating interdisciplinary teams investigating metastasis mechanisms and therapeutic innovation.

Slava Zieglerمشاهده پروفایل

پژوهشگر

• Chemical Biology
• Bioactive Small Molecules
• Target Identification
• +۳ مورد دیگر

Dr. Slava Ziegler is a Project Group Leader at the Department of Chemical Biology , Max Planck Institute of Molecular Physiology in Dortmund, Germany. His research focuses on identifying bioactive small molecules and elucidating their molecular targets and mechanisms of action through chemical proteomics, biochemical, biophysical and genetic approaches. Academic Appointments : Project Group Leader, Chemical Biology (2016-present) Education : Diploma in Biochemistry (Ruhr University Bochum), PhD in Biochemistry (MPI & Ruhr University), Postdoc at University Hospital Düsseldorf Research Interests center on: Phenotypic screening using Cell Painting assays Target identification for bioactive compounds Proteome and lipidome profiling Developmental signaling pathway inhibition Glucose transporter and glutaminase targeting Chemical genetics in cancer metabolism Notable Contributions include developing high-throughput screening workflows, discovering novel Hedgehog and TRPC inhibitors, and creating chemical probes for: Dihydroorotate Dehydrogenase RHOGDI PI4KIIIß IDO1 TAF1 Bromodomain 5-Lipoxygenase Collaborations with researchers across Europe and Japan have yielded significant insights into: Autophagy regulation Lysosomal membrane repair Microtubule destabilization Proteasome inhibition Neutrophil extracellular traps Embryonic stem cell reprogramming Contact : slava.ziegler@mpi-dortmund.mpg.de | +49 231 133-2424

Steven T. Hallerمشاهده پروفایل

دانشیار

• Molecular Mechanisms of End-Stage Renal Disease
• Cyanotoxin Exposure Effects in Pre-Existing Diseases
• Hypertension and Renal Disease
• +۳ مورد دیگر

Steven T. Haller is an Associate Professor of Medicine at the University of Toledo College of Medicine and Life Sciences. He serves as Director of the Jacobson Center for Clinical and Translational Research and Co-Director of the Women & Philanthropy Genetic Analysis Center. His work focuses on molecular mechanisms of end-stage renal disease and health impacts of cyanotoxin exposure. Education : B.S. in Biology/Chemistry (2003), M.S. in Molecular Basis of Disease (2005), Ph.D. in Biomedical Sciences (2012) - all from University of Toledo/Medical University of Ohio. Research Interests center on CD40 receptor signaling in renal inflammation/fibrosis and cyanotoxin effects in vulnerable populations. His lab develops therapeutic inhibitors for renal disease and investigates toxin impacts on respiratory/liver systems. Scientific Awards include American Heart Association Postdoctoral Fellowship (2013-2015), European Society of Hypertension Travel Awards (2014), and Young Investigator Award finalist status (2014). Publications highlight CD40 disruption in renal disease models, Na/K-ATPase signaling mechanisms, and environmental toxin impacts across multiple organ systems (2022-2025). His work bridges clinical nephrology, molecular cardiology, and environmental health. Collaborations span cardiovascular medicine, genetic analysis, and environmental research centers. Funded by Abbott, Inc., he maintains transparency regarding clinical research independence.

• Plant Stress Tolerance
• Calcium Signaling
• Chloroplast Development
• +۵ مورد دیگر

Markus Teige is a researcher at the Max Perutz Labs, affiliated with the Faculty of Life Sciences at the University of Vienna, in the Department of Biochemistry and Cell Biology. His work focuses on plant stress tolerance, calcium signaling, chloroplast development, protein phosphorylation, and organelle signaling networks. Current projects include Molecular mechanisms of plant stress tolerance (2021–2025) and Calcium regulation of chloroplast development & function (ongoing). Past projects include Auswirkungen von Virusinfektionen auf die Kalziumhomöostase (2020–2022). Research trends from his 62 publications emphasize calcium signaling in plant antiviral defense, chloroplast stress responses, and integrated multi-omics approaches to abiotic stress in crops like potato. His work bridges organelle physiology with whole-plant stress adaptation. Teige collaborates internationally on plant signaling and systems biology, contributing to Sustainable Development Goals (SDGs) related to climate-resilient agriculture and stress biology.

Juan Alonso-Serraمشاهده پروفایل

پژوهشگر

• Plant Biology
• Molecular Biology
• Biochemistry
• +۴ مورد دیگر

Juan Alonso-Serra is a University Researcher at the Organismal and Evolutionary Biology Research Program within the Faculty of Biological and Environmental Sciences at the University of Helsinki. His work integrates molecular, cellular, and organismal approaches to investigate fundamental mechanisms in plant development and environmental adaptation. His research focuses on plant biomechanics, molecular signaling, and evolutionary biology, with specific expertise in turgor pressure dynamics, cell wall architecture, and hormonal regulation of growth. Key investigations include water flux patterns in meristems, callose deposition in woody tissues, auxin-strigolactone crosstalk in tree architecture, and carbon sequestration feedback mechanisms. This interdisciplinary work bridges biochemistry, biophysics, and systems biology to unravel how mechanical and biochemical pathways co-regulate plant morphogenesis. Analysis of his 2021-2024 publications reveals a dominant theme in plant mechanobiology, where turgor-driven processes interact with molecular signaling to shape organ development. His studies employ advanced techniques including nano-architecture imaging, mutant phenotyping, and computational modeling, with consistent emphasis on translating cellular-scale mechanisms to whole-plant architectural outcomes. Recurring subfields include meristem function, cell wall dynamics, and hormone gradient formation across diverse plant systems. Dr. Alonso-Serra currently participates in the Horizon Europe-funded project Uncovering turgor sensing in the Arabid (2024-2026), supporting his research on mechanical force transduction in plant cells. While no formal student advising is documented, his collaborative network spans 14+ international institutions as evidenced by multi-author publications in high-impact journals including Nature Communications and PNAS .

• Plant Biotechnology
• Genetic Engineering
• Biochemical Engineering
• +۳ مورد دیگر

Dr. Jianfeng (Jay) Xu is a Professor of Biochemical Engineering at Arkansas State University's Beck College of Sciences & Mathematics, Department of Molecular Biosciences. He holds a Ph.D. and B.S. in Biochemical and Environmental Engineering from Dalian University of Technology, China. Education: Ph.D., Dalian University of Technology, China (Biochemical Engineering) B.S., Dalian University of Technology, China (Environmental Engineering) His research focuses on plant-based bioproduction platforms using genetic engineering and genome editing to enhance therapeutic protein and biofuel yields. He developed the "HypGP Engineering" technology, enabling over 500-fold protein yield increases in plant systems. Applications include oral medications for inflammatory bowel disease and bioenergy crop modifications for improved biomass digestibility. Recent publications emphasize plant cell engineering for therapeutic proteins, glycosylation optimization, biomass processing, and biomedical applications. His work has received federal funding from NIH, NSF, USDA, and DOE. Scientific contributions include 8 issued U.S. patents related to plant glycoprotein production and expression systems. Grants: National Institutes of Health (NIH) National Science Foundation (NSF) United States Department of Agriculture (USDA) Department of Energy (DOE) Patents: Growth hormone and interferon-alpha-2 glycoproteins in plants Designer glycomodules for protein expression Methods for hyp-glycosylation site prediction Dr. Xu leads the Xu Lab, pioneering plant cell systems for biopharmaceuticals and sustainable biofuels. His lab investigates macromolecular crowding effects, cell wall reconstruction, and recombinant protein trafficking mechanisms.

David I. Yuleمشاهده پروفایل

استاد

• Intracellular Calcium Signaling
• Exocrine Cell Physiology
• Signal Transduction
• +۳ مورد دیگر

David I. Yule, Ph.D., is a Professor at the University of Rochester School of Medicine and Dentistry , holding dual appointments in the Department of Pharmacology and Physiology and the Department of Medicine, Gastroenterology/Hepatology . His research focuses on intracellular calcium signaling in exocrine cells , particularly pancreatic acinar cells and salivary gland cells , investigating how IP3 receptors and ryanodine receptors regulate fluid secretion , enzyme release , and pathophysiological responses in diseases like acute pancreatitis and Sjögren's Syndrome . Ph.D., University of Liverpool (1989) B.S., Portsmouth Polytechnic (1985) Postdoctoral work: MRC Secretory Control Group, University of Liverpool and University of Michigan Yule's lab employs high-speed confocal microscopy , antisense technology , and fluorescence imaging to dissect agonist-specific signaling pathways and calcium release site organization . Current projects include studying IP3 receptor phosphorylation , genetic defects in calcium signaling linked to dry mouth diseases, and mitochondrial interactions in calcium dynamics. His recent 15 most influential publications span topics from IP3R isoform regulation in gluconeogenesis to calcium oscillation modeling and Bcl-2 family modulation of apoptotic signaling . Collaborative work with institutions like Stanford and KU Leuven has produced key insights into organellar calcium channels . Recipient of the Louis C. Lasagna Professorship in Experimental Therapeutics (2016) Awarded with the 2016 Convocation Award at University of Rochester As mentor, Yule supervises graduate students in multidisciplinary research, including projects on radiation-induced salivary dysfunction (Amanda Wahl, NIH F31 awardee) and mitochondrial Ca²⁺ handling . His lab maintains a 3D computational modeling partnership with J. Sneyd to integrate experimental data with theoretical frameworks.

Kathy Iovineمشاهده پروفایل

استاد

• Developmental Biology
• Regeneration
• Skeletal Morphogenesis
• +۴ مورد دیگر

Kathy Iovine serves as Professor and Department Chair at Lehigh University, leading research in skeletal development and regeneration using zebrafish models. Her work focuses on elucidating molecular mechanisms controlling bone growth through fin regeneration studies. Her primary research interests span developmental biology, regeneration, skeletal morphogenesis, cell-cell communication, and extracellular matrix dynamics. She investigates how connexin43 (Cx43)-mediated gap junctional communication coordinates skeletal growth and patterning, with emphasis on segment addition in zebrafish fins as the fundamental unit of bone growth. Key areas include semaphorin signaling, hyaluronic acid metabolism, and collagen-based actinotrichia structures. Analysis of her publication record reveals consistent exploration of Cx43-dependent networks across 15+ recent studies. Her work demonstrates how mutations in connexin43 disrupt fin length regulation through effects on cell proliferation and joint formation, identifying critical mediators like Sema3d and Hapln1a. The research integrates genetic, molecular, and cellular approaches to dissect pathways governing skeletal morphogenesis. Dr. Iovine directs an active research laboratory investigating the genetic basis of skeletal development. Her team has characterized how actinotrichia integrity signals between proliferating and differentiating cell compartments to coordinate growth, and how Cx43 regulates extracellular environment modifiers. Current efforts focus on validating additional genes within the Cx43-dependent network to uncover novel therapeutic targets for skeletal disorders.

Erik Sahaiمشاهده پروفایل

استاد

• Cell Biology
• Imaging
• Tumour Biology
• +۵ مورد دیگر

Erik Sahai is a Professor and Group Leader at the Francis Crick Institute in London, where he leads a research group focused on cancer biology, cell migration, and tumor microenvironment. He previously established his lab at the Cancer Research UK London Research Institute in 2004, which later became part of the Francis Crick Institute in 2015. Dr. Sahai's educational background includes: PhD in Biochemistry from University College London (1998) Postdoctoral training at the Institute of Cancer Research, UK (1998) Postdoctoral training at Albert Einstein College of Medicine, USA (2003) His research primarily focuses on understanding how cancer cells interact with their microenvironment, particularly examining cell migration, tumor heterogeneity, and mechanisms of therapy resistance. Dr. Sahai's work combines advanced imaging techniques with molecular and cellular biology approaches to study tumor progression and metastasis. His laboratory has made significant contributions to understanding how tumor-stroma interactions influence cancer progression and treatment response. Analysis of Dr. Sahai's recent publications reveals a strong emphasis on spatial tumor organization, cancer cell migration, and therapy resistance mechanisms. His work frequently employs advanced imaging technologies to visualize cellular dynamics within tumors. Recent research has increasingly incorporated computational approaches and artificial intelligence to analyze complex tumor ecosystems. The interdisciplinary nature of his work spans cancer biology, cell signaling, immunology, and bioengineering. Dr. Sahai has received recognition through numerous high-impact publications in prestigious journals including Nature, Cell, Nature Cell Biology, and Cancer Discovery. His collaborative approach is evident in the extensive co-authorship networks spanning multiple institutions and disciplines. As a group leader, Dr. Sahai mentors numerous PhD students and postdoctoral researchers, contributing to the training of the next generation of cancer researchers. His laboratory maintains collaborations with clinicians to ensure translational relevance of their basic research findings. Dr. Sahai's laboratory utilizes state-of-the-art facilities at the Francis Crick Institute, including advanced light microscopy, flow cytometry, and computational resources to investigate complex tumor biology questions.

• Structural Biology
• Chemical Biology
• Cancer Therapeutics
• +۵ مورد دیگر

Alex Bullock is Professor of Structural and Chemical Biology at the University of Oxford, where he leads the Growth Factor Signalling and Ubiquitination research group. His multidisciplinary work bridges structural biology, chemical biology, and therapeutic development for cancer and rare diseases. He holds a PhD from the University of Cambridge and completed postdoctoral work at the University of Washington and Oxford, supported by a Wellcome Fellowship. His research focuses on: Disease-causing mutations in kinases (e.g., ALK2 in fibrodysplasia ossificans progressiva and brain tumors) E3 ubiquitin ligase neofunction (e.g., KBTBD4 in medulloblastoma) Development of PROTACs for targeted protein degradation Small-molecule inhibitors for undruggable targets He leads a phase 2 clinical trial for the ALK2 inhibitor saracatinib and collaborates globally with institutions including Stanford, Harvard, and the University of Edinburgh. His publications emphasize kinase inhibition, ubiquitin pathways, and structure-guided drug design, with recent work on KEAP1-Nrf2 inhibitors, E3 ligases, and chemical probes for kinases like CDKL5/GSK3. Awards include the Wellcome Fellowship . He engages with disease foundations (FOP Friends, Brain Tumour Charity) and public outreach.

• Cellular Metabolism
• Redox Homeostasis
• Cell Death Pathways
• +۶ مورد دیگر

Rodrigo Franco Cruz serves as a Professor in the Department of Veterinary and Biomedical Sciences at the University of Nebraska-Lincoln, where he leads research on cellular signaling mechanisms linking metabolism, redox balance, and disease pathogenesis. His academic credentials include: Postdoctoral Fellow (2004-2009) at the Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, NIH PhD in Sciences (Biomedical sciences, 2000-2004) from the Cell Physiology Institute, National University of Mexico (UNAM) B.S. in Biology (1996-2000) from the School of Sciences, National University of Mexico (UNAM) The Franco lab investigates how mitochondrial dysfunction and disrupted protein quality control trigger cell death pathways (apoptosis, necrosis, autophagy) in neurological disorders and cancer. Research specifically targets neurotoxicity from environmental exposures, neurodegenerative processes, brain ischemia, and oncological mechanisms through molecular signaling studies. Rodrigo Franco Cruz directs the Franco lab, which operates from VBS 210 at UNL, focusing on identifying therapeutic targets for diseases involving energy failure and oxidative stress.